Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., said data from its phase II study with Azedra (Ultratrace iobenguane I 131) for the treatment of ultra-orphan indications pheochromocytoma and paraganglioma were highlighted during an oral presentation at the European Association of Nuclear Medicine Congress in Hamburg, Germany.